Brief: CANbridge To Continue CAN008 Phase 2 Trial In Glioblastoma Multiforme In China Based On Interim Analysis Of Independent Data Monitoring Committee
03/07/2023 13:09
July 3 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* CANBRIDGE TO CONTINUE CAN008 PHASE 2 TRIAL IN GLIOBLASTOMA
MULTIFORME (GBM) IN CHINA BASED ON INTERIM ANALYSIS OF
INDEPENDENT DATA MONITORING COMMITTEE
Source text for Eikon: ID:nBw7pT9mza
Further company coverage: 1228.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares